Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

98P - A stable NGS method to detect microsatellite instability status across different batches, sequencing platforms and cancer types

Date

16 Sep 2021

Session

ePoster Display

Topics

Targeted Therapy

Tumour Site

Gastric Cancer;  Endometrial Cancer;  Colon and Rectal Cancer

Presenters

Chenghong Lin

Citation

Annals of Oncology (2021) 32 (suppl_5): S382-S406. 10.1016/annonc/annonc686

Authors

C. Lin1, S. Chen1, B. Jin1, A. Zhang1, L. Ruan2, H. Dong3, X. Li1

Author affiliations

  • 1 Innovation Business Unit, Amoy Diagnostics Co., Ltd., 361026 - Xiamen/CN
  • 2 Product Business Unit, Amoy Diagnostics Co., Ltd., 361026 - Xiamen/CN
  • 3 Innovation Business Unit, Amoy Diagnostics Co., Ltd., 200433 - SHANG HAI/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 98P

Background

DNA mismatch repair deficiency usually causes microsatellite loci length alterations during DNA replication, which is known as microsatellite instability (MSI). Recently, Next-Generation Sequencing (NGS) based MSI detection methods are very popular. However, they often show poor consistency across sequencing batches, platforms and cancer types. There is great need to develop a unified method to detect MSI status with high producibility in different NGS labs.

Methods

We construct a mixed reference dataset by mixing multiple population of MSI-negative samples from different sequencing batches, platforms and cancer types. We define the characteristic value for each microsatellite markers within each sample by the number of repeats of different lengths. Therefore, it is possible to match and acquire an optimal subset of reference for each sample from the constructed mixed reference datasets. We calculated the baseline reference value based on the mean and standard deviation value of the characteristic value at each microsatellite loci across the reference subset. Then we compared characteristic value against baseline reference value at each locus to assess the instability of microsatellite loci. Finally, the fraction of unstable loci out of the total number of loci was calculated to assess the instability of each sample.

Results

We evaluated 337 MSI-positive samples and 905 MSI-negative samples from 3 cancer types (colorectal cancer, gastric cancer and endometrial cancer), 6 sequencing chips (MiSeq, MiniSeq-High Throughput, NextSeq-Mid Throughput, NextSeq-High Throughput, MGI200 and MGI2000) from 2 sequencing platforms (Illumina and MGISEQ) and 17 sequencing batches in total. Compared to the well-established gold standard PCR plus capillary electrophoresis methodology, our approach shows high sensitivity (99.41%) and specificity (100%).

Conclusions

Our NGS-based MSI detection method provides an effective, robust and accurate performance to determine MSI status compared to traditional method, which can apply to samples from different cancer types with different sequencing platforms and chips, without the need to creat specific reference set for each NGS lab.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

AmoyDx.

Funding

AmoyDx.

Disclosure

C. Lin, S. Chen, B. Jin, A. Zhang, L. Ruan, H. Dong, X. Li: Financial Interests, Institutional, Full or part-time Employment: AmoyDx.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.